ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 0737 • ACR Convergence 2021

    Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression

    Sumir Brahmbhatt1, Ahsan Iqbal1, Fatemeh Farshami2, Maheswari Muruganandam3, Jaren Trost4, David Cisneros5, Adnan Kiani3, N. Suzanne Emil3, Sharon Nunez1, William Hayward6, Philip Band7 and Wilmer Sibbitt3, 1UNM, Albuquerque, NM, 2University of New Mexico, Albuquerque, MD, 3University of New Mexico, Albuquerque, NM, 4Optum, Albuquerque, NM, 5University of New Mexico School of Medicine, Albuquerque, NM, 6New Mexico Highlands University, Las Vegas, NM, 7NYU SOM, New York, NY

    Background/Purpose: To explore an alternative to standard extended knee arthrocentesis using pneumatic compression of the flexed knee.Methods: Using a paired sample design, 41 consecutive effusive…
  • Abstract Number: 0877 • ACR Convergence 2021

    Association of HCQ Blood Levels with Type 1 and 2 SLE Activity

    Kai Sun1, Amanda Eudy2, Jennifer Rogers1, Lisa Criscione-Schreiber1, Rebecca Sadun2, Jayanth Doss2, Kelley Brady3, Roberta Alexander3, John Conklin3, Rory Bloch3 and Megan Clowse4, 1Duke University School of Medicine, Durham, NC, 2Duke University, Durham, NC, 3Exagen Inc., Vista, CA, 4Duke University, Chapel Hill, NC

    Background/Purpose: HCQ levels reflect adherence and have been shown to correlate with SLE outcomes. However, HCQ levels have not been studied in the context of…
  • Abstract Number: 1299 • ACR Convergence 2021

    Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network

    Peter Izmirly1, Maria Dall'Era2, Kenneth Kalunian3, Kristina Deonaraine1, Mimi Kim4, Philip Carlucci1, Jessica Li5, Andrea Fava5, H. Michael Belmont6, Chaim Putterman7, Jennifer Anolik8, Betty Diamond9, David Wofsy10, Diane Kamen11, Judith James12, Accelerating Medicines Partership (AMP) RA/SLE Network13, Deepak Rao14, The Accelerating Medicines Partnership in SLE Network15, Michelle Petri16, Jill Buyon6 and Richard Furie17, 1New York University School of Medicine, New York, NY, 2University of California San Francisco, Corte Madera, CA, 3UC San Diego, La Jolla, CA, 4Albert Einstein College of Medicine, Larchmont, NY, 5Johns Hopkins University, Baltimore, MD, 6NYU School of Medicine, New York, NY, 7Albert Einstein College of Medicine, Bronx, NY, 8University of Rochester Medical Center, Rochester, NY, 9Northwell Health, Manhasset, NY, 10University of California San Francisco, San Francisco, CA, 11Medical University of South Carolina, Charleston, SC, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13Brigham and Women's Hospital, Everett, MA, 14Brigham and Women's Hospital, Boston, MA, 15Multiple Institutions, Multiple Cities, 16Johns Hopkins University School of Medicine, Baltimore, MD, 17Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY

    Background/Purpose: The Accelerating Medicines Partnership (AMP) Lupus Network was established with the goal of applying novel technologies to the interrogation of blood and tissue samples…
  • Abstract Number: 1933 • ACR Convergence 2021

    Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus (SLE) in United States Patients: Data from the COVID-19 Global Rheumatology Alliance

    Manuel Ugarte-Gil1, Graciela Alarcn2, Andrea Seet3, Zara Izadi3, Ali Duarte-Garcia4, Emily Gilbert5, Maria Valenzuela-Almada6, Leanna Wise7, Jeffrey Sparks8, Tiffany Hsu9, Kristin D'Silva10, Naomi Patel10, Emily Sirotich11, Jean Liew12, Jonathan Hausmann13, Paul Sufka14, Rebecca Grainger15, Suleman Bhana16, Wendy Costello17, Zachary Wallace18, Lindsay Jacobsohn19, Anja Strangfeld20, Elsa Frazão Mateus21, Kimme Hyrich22, Laure Gossec23, Loreto Carmona24, Saskia Lawson-Tovey22, Lianne Kearsley-Fleet25, Martin Schaefer26, Pedro Machado27, Philip Robinson28, Milena Gianfrancesco3 and Jinoos Yazdany3, 1Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 2University of Alabama at Birmingham, Birmingham, AL, 3University of California San Francisco, San Francisco, CA, 4Mayo Clinic, Rochester, MN, 5Mayo Clinic, Jacksonville, FL, 6Division of Rheumatology, Mayo Clinic, Rochester, MN, 7LAC+USC/Keck Medicine of USC, Pasadena, CA, 8Brigham and Women's Hospital, Boston, MA, 9Brigham and Women's Hospital, Jamaica Plain, MA, 10Massachusetts General Hospital, Boston, MA, 11McMaster University, Hamilton, ON, Canada, 12Boston University, Boston, MA, 13Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 14HealthPartners, Eagan, MN, 15University of Otago, Wellington, New Zealand, 16Crystal Run Health, Montvale, NJ, 17Irish Children's Arthritis Network, Bansha, Ireland, 18Massachusetts General Hospital, Newton, MA, 19University of California San Francisco, Antioch, CA, 20Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 21Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 22University of Manchester, Manchester, United Kingdom, 23Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, 24Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, 25Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 26German Rheumatism Research Center, Berlin, Germany, 27Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 28Faculty of Medicine, The University of Queensland, Herston, Australia

    Background/Purpose: Hispanic and African American race/ethnicities have been associated with poor COVID-19 outcomes in the general population and in rheumatic disease patients within the COVID-19…
  • Abstract Number: 0401 • ACR Convergence 2021

    Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study

    John Pauling1, Lan Yu2, Christopher Denton3, Tracy Frech4, Ariane Herrick5, Laura Hummers6, Lesley Ann Saketkoo7, Ami Shah8, Dinesh Khanna9 and Robyn Domsic2, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2University of Pittsburgh, Pittsburgh, PA, 3University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 4University of Utah, Salt Lake City, UT, 5University of Manchester, Salford, United Kingdom, 6Johns Hopkins Univerisity, Baltimore, MD, 7University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, 8Johns Hopkins Rheumatology, Baltimore, MD, 9University of Michigan, Ann Arbor, MI

    Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome (PRO) instrument devised to assess the severity and impact of…
  • Abstract Number: 0739 • ACR Convergence 2021

    Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)

    Uta Kiltz1, Eerik Ahomaa2, Björn Buehring1, Xenofon Baraliakos1, David Kiefer1, Jaclyn-Dalisay Leicht1 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany

    Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
  • Abstract Number: 0925 • ACR Convergence 2021

    Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs

    Philip Mease1, Robert McLean2, Taylor Blachley2, Maya Marchese2, Laura Anatale-Tardiff3, Christopher Saffore4, Danny Quach5, Ana Biljan6 and Alexis Ogdie7, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2CorEvitas, LLC, Waltham, MA, 3CorEvitas, Waltham, MA, 4AbbVie, North Chicago, IL, 5AbbVie Inc., North Chicago, IL, 6Abbvie Inc., Chicago, IL, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research…
  • Abstract Number: 1344 • ACR Convergence 2021

    Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs

    Alexis Ogdie1, Robert McLean2, Maya Marchese2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Kevin Douglas5, Danny Quach5 and Philip Mease6, 1University of Pennsylvania, Philadelphia, PA, 2CorEvitas, LLC, Waltham, MA, 3CorEvitas, Waltham, MA, 4AbbVie, North Chicago, IL, 5AbbVie Inc., North Chicago, IL, 6Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

    Background/Purpose: Minimal disease activity (MDA) is a common goal for disease control when managing PsA. The aim of this study was to assess the association…
  • Abstract Number: 0402 • ACR Convergence 2021

    What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?

    Alain Lescoat1, Susan Murphy2, Yen Chen3, Nadia Vann1, David Cella4 and Dinesh Khanna3, 1Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2University of Michigan, Grosse Ile, MI, 3University of Michigan, Ann Arbor, MI, 4Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Limited cutaneous SSc (lcSSc) affects approximately 60-70% of SSc patients but drug development and therapeutic research has largely focused on the more severe diffuse…
  • Abstract Number: 0751 • ACR Convergence 2021

    Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?

    Philip Mease1, Vibeke Strand2, Dan Furst3, Evan Siegel4, Melissa Mcilraith5, Elaine Husni6 and M. Cameron Hay7, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Stanford University School of Medicine, Portola Valley, CA, 3University of California Los Angeles, Los Angeles, CA, 4Arthritis and Rheumatism Associates, Potomac, MD, 5M.Mc. Consulting, Dallas, TX, 6Cleveland Clinic, Cleveland, OH, 7Miami University (Ohio), Oxford, OH

    Background/Purpose: Psoriatic Arthritis (PsA) affects multiple attributes of patient health; to assess treatment effectiveness a compilation of Patient Reported Outcomes (PRO) have been utilized. While…
  • Abstract Number: 1026 • ACR Convergence 2021

    Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study

    Sung Kyung Cho1, Lorinda Chung2 and David Fiorentino3, 1University of Texas Southwestern, Dallas, TX, 2Stanford University, Palo Alto, CA, 3Stanford University, Redwood City, CA

    Background/Purpose: Dermatomyositis (DM) is a chronic idiopathic inflammatory myopathy with variable clinical course, but little is known regarding factors associated with remission of disease. We…
  • Abstract Number: 1410 • ACR Convergence 2021

    Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis

    Kathleena D'Anna1, David Lim2, Lorena Salto1 and Mehrnaz Hojjati1, 1Loma Linda University Health, Loma Linda, CA, 2Loma Linda University Health, Redlands, CA

    Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in North America, typically affecting Caucasian female adults over 50 years of age. Flares…
  • Abstract Number: 0441 • ACR Convergence 2021

    A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis

    Pedro Machado1, Richard Barohn2, Michael McDermott3, Thomas Blaetter4, Tom Lloyd5, Aziz Shaibani6, Miriam Freimer7, Anthony Amato8, Emma Ciafaloni3, Sarah Jones9, Tahseen Mozaffar10, Summer Gibson11, Matthew Wicklund12, Todd Levine13, Claus Sundgreen4, Tim Carstensen4, Karen Bonefeld4, Anders Jørgensen4, Karina Phonekeo4, Andrew Heim14, Laura Herbelin14, Michael Hanna15 and Mazen Dimachkie14, 1Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 2University of Missouri - Columbia, Columbia, MO, 3University of Rochester, Rochester, NY, 4Orphazyme A/S, Copenhagen, Denmark, 5Johns Hopkins University, Baltimore, MD, 6Nerve and Musle Center, Houston, TX, 7Ohio State University, Columbus, OH, 8Brigham and Women's Hospital, Boston, MA, 9University of Virginia, Charlottesville, VA, 10University of California Irvine, Irvine, CA, 11University of Utah, Salt Lake City, UT, 12University of Colorado, Denver, CO, 13Phoenix Neurological Associates, Phoenix, AZ, 14University of Kansas Medical Center, Kansas City, KS, 15University College London, London, United Kingdom

    Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
  • Abstract Number: 0756 • ACR Convergence 2021

    Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis

    R Naveen1, Darpan R Thakare2, Vikas Agarwal2, Rohit Aggarwal3 and Latika Gupta1, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Changing landscape of patient care from in-person to virtual telemedicine-based consultation in times of a global pandemic has necessitated a wider use of patient-centered…
  • Abstract Number: 1154 • ACR Convergence 2021

    What Do Patients Know About Biosimilars and How Satisfied Are They with the Educational Process? – A Systematic Comparison Between Rheumatologists and Nurse Specialists, Including Effects of Multiswitching

    Sabina Gall, Uta Kiltz, Tanja Kobylinski, Ioana Andreica, Kristina Vaupel, Xenofon Baraliakos and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany

    Background/Purpose: The market share of biosimilars (bsDMARDs) is steadily growing, not only in rheumatologic care. Although data on efficacy, efficiency and safety have been generated…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology